Pulmonary Pharmacology

Preface W.S. FRED WONG 1. Genomic and non-genomic effects of glucocorticoids in respiratory diseases Zhao-Yong Lee and Thai Tran 2. Recent developments in the use of monoclonal antibodies targeting the type 2 cytokines for severe asthma treatment Garry M. Walsh 3. Phosphodiesterase inhibitors and lung diseases Ivana Stolfa and Clive Page 4. Prospects for macrolide therapy of asthma and COPD Michael J. Parnham, Virginia Norris, Jennifer A. Kricker, Thorarinn Gudjonsson, and Clive P. Page 5. Targeting the renin angiotensin system for respiratory diseases Phyllis X.L. Gan, W. Liao, Kira M. Linke, D. Meid, X.D. Wu, and W.S. Fred Wong 6. Progress in the development of kinase inhibitors for treating asthma and COPD Nathaniel McClean, Jeffery D. Hasday, and Paul Shapiro 7. Anti-fibrotic strategies and pulmonary fibrosis Avanka Gunatilaka, Stephanie Zhang, Wan Shun Daniel Tan, and Alastair G. Stewart 8. Novel treatments against airway inflammation in COPD based on drug repurposing Rui Chen, Yuting Cui, and Judith C.W. Mak 9. Senotherapy for lung diseases Peter J. Barnes 10. Delivery technology of inhaled therapy for asthma and COPD Michael Y.T. Chow, Harry W. Pan, and Jenny K.W. Lam